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Gram-negativebacteriautilize specializedmachinery to translo-
cate drugs and protein toxins across the inner and outer mem-
branes, consisting of a tripartite complex composed of an inner
membrane secondary or primary active transporter (IMP), a
periplasmic membrane fusion protein, and an outer membrane
channel. We have investigated the assembly and function of the
MacAB/TolC system that confers resistance tomacrolides inEsch-
erichia coli. The membrane fusion protein MacA not only stabi-
lizes the tripartite assembly by interacting with both the inner
membrane protein MacB and the outer membrane protein TolC,
but also has a role in regulating the function of MacB, apparently
increasing its affinity for both erythromycin and ATP. Analysis of
the kinetic behavior of ATP hydrolysis indicated that MacA pro-
motes and stabilizes the ATP-binding form of the MacB trans-
porter. For the first time, we have established unambiguously the
dimericnatureof anoncanonicABCtransporter,MacBthathasan
N-terminal nucleotide binding domain, bymeans of nondissociat-
ing mass spectrometry, analytical ultracentrifugation, and atomic
force microscopy. Structural studies of ABC transporters indicate
thatATPisboundbetweenapairofnucleotidebindingdomains to
stabilize a conformation inwhich the substrate-binding site is out-
ward-facing.Consequently, ourdata suggest that in thepresenceof
ATPthesameconformationofMacBispromotedandstabilizedby
MacA. Thus,MacAwould facilitate the delivery of drugs byMacB
to TolC by enhancing the binding of drugs to it and inducing a
conformation of MacB that is primed and competent for binding
TolC. Our structural studies are an important first step in under-
standing how the tripartite complex is assembled.
Gram-negative bacteria utilize transport systems composed
of a tripartite assembly of proteins that span both the inner and
outer membranes to pump cytotoxic compounds, such as
antibiotics (1), and protein toxins (2), such as -hemolysin,
from the cell. These assemblies are composed of inner
(IMP)7 and outer (OMP) membrane proteins that are con-
nected by a periplasmic membrane fusion protein (MFP),
which is anchored to the innermembrane. The systems respon-
sible for toxin extrusion invariably utilize an ABC transporter
as the IMP (2), whereas those involved in antibiotic extrusion
largely utilize proton antiporters (1), but there are some that
utilize ABC transporters (3). The sameOMP can be utilized for
both drug and toxin extrusion; for example, TolC functions
with antibiotic H antiporters, such as AcrB that belongs to the
regulation nodulation cell division family of transporters (4, 5),
with ABC transporters, such as the macrolide transporter
MacB (3), and with HlyB that extrudes the protein toxin -he-
molysin (2).
Although the structure of an assembled tripartite complex
has not yet been determined, the structures of a few individual
components have been elucidated. Most significantly, the
structure of the RND transporter AcrB (6, 7) and of its cognate
MFP, AcrA (8), and OMP, TolC (9), have been determined.
Both AcrB and TolC are organized as homotrimers. The AcrB
trimer has a periplasmic headpiece formed by the loops
between helices 1 and 2 and helices 7 and 8. The headpiece has
a funnel-shaped internal cavity that is connected by a pore to a
large central cavity formed between the periplasmic and mem-
brane domains. The trimeric TolC forms a cylindrical channel
with a structure that is arranged into two major domains as
follows: a -barrel in the outer membrane and a periplasmic
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-helical barrel. It has been proposed, and is supported by
cross-linking studies (10), that the six hairpins from the upper
headpiece of the AcrB trimer contact the tips of the six helical
pairs of the TolC trimer (11) to form a continuous path across
the periplasmic space. The structure of AcrA revealed an elon-
gated monomer that is composed of three subdomains as fol-
lows: a -barrel, a lipoyl domain, and a 58-Å-long -helical
hairpin (8). AcrA has been reported to interact with both TolC,
via the -helical hairpin (12), and AcrB, via the -domains (13),
to stabilize the tripartite complex (4, 5).
Several lines of evidence suggest that assembly of the tripar-
tite complex is a dynamic process that induces conformational
changes in the protein components. The structures of a number
ofOMPs indicate that the channel is closed at one or both sides,
requiring conformational changes to allow passage of the sub-
strate (11–14). Several studies support the hypothesis that a
small number of key interactions between adjacent coiled-coils
of the OMP are broken to allow the inner coils to untwist and
realign with the outer coils, thereby opening theOMP entrance
aperture (11, 15–17). The conformational flexibility of AcrA
may enable realignment of the coiled-coil to stabilize the open
state of TolC (8, 11, 15). Recently, the structures of a number of
different conformations of AcrB have been determined that
support amechanisticmodel inwhich there is a functional rota-
tion in the periplasmic domains driving transfer of drugs into
the OMP (18–21). The conformational asymmetry in the IMP
is also reflected in the asymmetry in the open state of the OMP
TolC (11). Such conformational changes in AcrB could be
transmitted toTolC viaAcrA. Furthermore, studies of the RND
transporter AcrD from Escherichia coli, whose typical sub-
strates, aminoglycosides, are not expected to diffuse spontane-
ously across the lipid bilayer, revealed that only whenAcrDwas
reconstitutedwithAcrAwas it able to take up aminoglycosides,
implying that AcrA is needed to “activate” AcrD (22). Collec-
tively, these findings suggest that the MFP supports conforma-
tional changes in both the IMP and OMP.
We have sought to further investigate the assembly of the
tripartite complex using the MacABTolC system responsible
for the extrusion of macrolides from E. coli (3). To date this is
the only tripartite pump for antibiotics that has been shown to
utilize an ABC transporter, MacB, which has a novel architec-
ture, consisting of a four-helix transmembrane domain, an
N-terminal cytoplasmic nucleotide binding domain (NBD),
and a large periplasmic domain formed by the loops connecting
helices 1 and 2 (3, 23). The fact that the ATPase activity of the
transporter can bemonitored, using purified proteins, provides
an additional tool for elucidating how its activity is modulated
by assembly and disassembly of the tripartite complex. Indeed,
recent studies, reported while this work was in progress, estab-
lished that the MFP MacA modulates the steady-state ATPase
activity of the IMP MacB (24). Our studies have confirmed
these findings and, by undertaking pre-steady-state analysis of
the kinetics, extended them by identifying how MacA modu-
lates the ATPase mechanism of MacB. In addition, we have
established that MacA also increases the capacity of MacB for
binding erythromycin. This behavior provides a rationale for
the retention of MacA by related systems from Gram-positive
bacteria, such as Staphylococcus aureus, which lack an outer
membrane and OMP (supplemental Fig. 1). Such analyses will
not only have a bearing on understanding the function of tri-
partite drug-pumps but also of related toxin transporters.
EXPERIMENTAL PROCEDURES
Strains and Plasmids—The E. coli strains and plasmids used
are described in supplemental Table 1, and the primers used for
construction of plasmid vectors are described in supplemental
Table 2.
Protein Overexpression and Purification—All the proteins
used in this study were purified as fusion proteins with a six-
histidine tag from E. coli overexpressing strains according to
the protocols given in the supplemental material.
Pulldown Assays—For pulldown assays, proteins were over-
expressed with a C-terminal S-tag for use with the cognate pro-
tein that was His-tagged. Membrane pellets, dissolved in deter-
gent, or cell supernatant containing the S-tagged prey protein
were mixed with 2 mg of purified His-tagged bait-protein. The
mixture was loaded onto a Ni2-charged Hitrap chelating col-
umn (GE Healthcare), so that the bait-protein could be immo-
bilized on the column along with the prey-protein if they inter-
act. The column was then washed with 15–20 column volumes
of Tris buffer containing 75–100 mM imidazole and Triton
X-100 (0.2% (v/v)) to eliminate any false-positive results
because of nonspecific interactions. The bait-prey protein com-
plex was eluted with 500 mM imidazole Tris buffer, containing
Triton X-100 (0.2% (v/v)), and SDS-PAGEwas used to visualize
the bait- and prey-proteins. A Western blot was performed
with anti-S-tag antibodies to confirm the presence of the
S-tagged prey-protein.
Growth Curve Analyses—E. coli cells, of strain KAM3(DE3),
harboring plasmids were grown at 37 °C, with shaking at 200
rpm, until the cell density gave an A600 of 0.5, when 0.05–0.1
mM isopropyl 1-thio--D-galactopyranoside was added to the
cells. The cells were grown for a further 3 h, when the cells were
dilutedwith 2YTmedia containing 100g/ml erythromycin,
and the growth curve was recorded over the next 12 h. For
experiments to measure the loss in growth because of erythro-
mycin, cells were grown for 3 h in the absence and presence of
50 g/ml erythromycin, and the growth loss is the ratio of the
A600 values.
Analytical Ultracentrifugation—Sedimentation equilibrium
measurements were performed using a BeckmanOptimaXL-A
analytical ultracentrifuge equipped with both absorbance and
interference optics. 100 l of MacB in buffer 1 (20 mM Tris, pH
8.0, 150 mM NaCl, 1% w/v glycerol, and 0.006% (w/v) DDM)
supplementedwith 10, 25, or 50%D2Owas placed in the sample
compartment of a Epon double-sector centerpiece, and 110 l
of buffer 1 was placed in the reference compartment. The final
protein concentrations used in the runs were between 0.5 and
1.0 mg/ml. The D2O was used to match the density of the sol-
vent to the density of the detergent as described previously (25)
The sampleswere centrifuged at 283K (10 °C) and 10,000, 15,000,
and25,000rpmusinganAn60-Ti rotor.Scanswereacquiredusing
theabsorbanceoptical system15hafter thestartof theexperiment
and in 1-h intervals until equilibriumwas attained. Sedimentation
velocity measurements were performed using the same hardware
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at 55,000 rpm at 10 °C in buffer 1. The details of the data analysis
are given as supplemental material.
Mass Spectrometry—Analyses were performed in a nanoflow
ES mass spectrometer Q-ToF2 (Micromass). The following
experimental parameters were used to recordmass spectra of 2
mg/ml MacB in the Q-ToF2 instrument: needle voltage of 1.5
kV and MCP 2350 V.
Atomic Force Microscopy—MacB was diluted to a final con-
centration of 1 g/ml, and 45 l of the sample was allowed to
adsorb to freshly cleaved mica. Imaging in air was performed
with a Multimode atomic force microscope (Digital Instru-
ments, Santa Barbara, CA) in tapping mode. The silicon canti-
levers containing a diamond-like extratip had a drive frequency
of 300 kHz and a specified spring constant of 40 newtons/m
(MikroMasch, Portland, OR), and the applied imaging force
was kept as low as possible (target amplitude 1.6–1.8 V and
amplitude set-point 1.3–1.5 V). The molecular volumes of
the protein particleswere determined fromparticle dimensions
based on AFM images (see supplemental material).
ATPase Assays—An EnzChek phosphate assay kit (Invitro-
gen) was used to determine theATPase activity ofMacB hydro-
lyzing MgATP to release phosphate, when the reactants were
mixed in a stopped-flow device (see supplemental material).
Generally, 2.3 M protein was mixed with varying concentra-
tions of ATP, up to 4 mM, in the presence of 6 mM MgCl2, to
ensure that all the ATP was complexed with Mg2. In control
experiments, noATPase activity was apparent in the absence of
Mg2. Generally, for MacB alone, the hydrolysis of ATP was
characterized by a Pi burst, whichwas of near equivalence to the
MacB concentration, consistent with the ATPase activity being
attributable to MacB, rather than any contaminant proteins.
Quantification of Erythromycin Binding to Affinity-purified
Mac Proteins—The equilibrium binding of [N-methyl-14C]eryth-
romycin to purified Mac proteins was determined by rapid filtra-
tion and quantification of the radioactivity remaining on 0.2-m
filters as outlined in the supplemental material.
FIGURE 1.MacA interacts with bothMacB and TolC. A, overexpression and
purification of MacA, MacB, and TolC. An SDS-polyacrylamide gel of purified
MacB (lane 1), MacA (lane 2), and TolC (lane 3) is shown. The purified His-
tagged MacB and TolC proteins were used as bait, immobilized on a Ni2-
agarose column, over which a slurry of either detergent-solubilized mem-
branes (e.g. from strains overexpressing S-tagged MacA or TolC) or soluble
proteins (e.g. from strains overexpressing S-tagged20MacA) was passed to
test whether the cognate proteins from the tripartite pump could be pulled
out of this complexmixture of proteins. B,pulldownofMacAbyMacB. 1st and
2nd lanes, SDS-polyacrylamide gel of immobilized His-taggedMacB (1st lane)
and the detergent-solubilized membranes from cells overexpressing the
S-taggedMacA (2nd lane). 3rd to 11th lanes,Western blot using antibodies to
the S-tag (1:5000 dilution) onMacA. The pulldown assay was performedwith
His-taggedMacB immobilized on a Ni2-agarose column, over which a slurry
of detergent-solubilized membranes from cells overexpressing S-tagged
MacAwas passed (7th to 9th lanes). The flow-through (9th lane), 100mM imid-
azolewash (8th lane), and the 500mM imidazole elution (7th lane) were tested
for thepresenceofMacA,whichwasnowalsodetected in theelution fraction,
indicating that it was bound to MacB. A negative control experiment was
performed in the absence of immobilized MacB in which MacA was passed
through a Ni2-agarose column (3rd to 5th lanes), and the flow-through (5th
lane), 100 mM imidazole wash (4th lane), and the 500 mM imidazole elution
(3rd lane) were tested for the presence of MacA, which was only found in the
flow-through (5th lane), establishing that S-taggedMacAdoesnotbind to the
column. These results indicate that MacB can pull MacA from a complexmix-
tureofmembraneproteins. PurifiedHis-taggedMacBdidnot cross-reactwith
the antibodies to the S-tag (10th lane). C, pulldown of MacA by TolC. An SDS-
polyacrylamide gel (lanes 1–8) for the pulldown of S-tagged MacA by His-
tagged TolC and the corresponding Western blot (lanes 1–8) probed with
antibodies (1:5000 dilution) to the S-tag on MacA. Purified His-tagged TolC
was immobilized on a Ni2-agarose column (lanes 1 and 1); a slurry of deter-
gent-solubilized membranes from cells overexpressing S-tagged MacA was
passed through the column and the proteins in the flow-through (lane 2 and
2), released by washing the column with 100 mM imidazole (lanes 3 and 3)
and eluted with 500 mM imidazole (lanes 4 and 4), were detected. As a neg-
ative control, S-taggedMacAwaspassed through the column (lanes 6 and 6),
in the absenceof immobilized TolC, and the columnwaswashedwith 100mM
(lanes 7 and 7) and 500 mM (lanes 8 and 8). Comparing lane 4 and 8 dem-
onstrates that MacA is only bound to the column in the presence of TolC,
indicative of its interaction with TolC. D, pulldown of TolC by MacB. An SDS-
polyacrylamide gel (lanes 1–4) for the pulldown of S-tagged TolC by His-
tagged MacB and the corresponding Western blot (lanes 1–4) probed with
antibodies (1:5000 dilution) to the S-tag on TolC. Purified His-tagged MacB
was immobilized on a Ni2-agarose column (lanes 1 and 1), and a slurry of
detergent-solubilized membranes from cells overexpressing S-tagged TolC
was passed through the column (lane 3 and 3), which was thenwashedwith
75 mM imidazole (lanes 4 and 4), and bound proteins were eluted with 500
mM imidazole (lanes 5 and 5). A weak band, which was not present in the
absence of immobilized MacB, was apparent in lane 5, indicative of a weak
interaction between MacB and TolC. A control experiment was performed in
the absence of immobilized MacB in which lC was passed through a Ni2-
agarose columnand the flow-through (lane6), the100mMimidazolewash (lane
7), and the 500 mM imidazole elution (lane 8) were tested for the presence
of TolC, which was only found in the flow-through (lane 6), establishing that
S-tagged TolC does not bind to the column. A protein Mr marker was run in
lane 2. E, pulldown of N-terminal truncatedMacA byMacB. An SDS-polyacryl-
amide gel shows the His-tagged MacB (lane 1) that was immobilized on a
Ni2-agarose column (lane 1), a slurry of cytoplasmic proteins released by
disruption of cells overexpressing S-tagged 20-MacA (lane 2), which was
passed through the column, over immobilized MacB, and the proteins in the
flow-through detected (lane 3); the proteins were released by washing the
columnwith100mM imidazole (lane 4); and theproteinswereelutedwith500
mM imidazole (lane 5). A Western blot was performed on each of the corre-
sponding protein fractions (indicated with 1–5) using antibodies to the
S-tag (1:5000dilution) todetect S-taggedMacA. The elutionofMacB yields an
extra, low Mr, band on the SDS-polyacrylamide gel that corresponds to that
expected for MacA (lane 5) and was identified as such by Western blotting
(lane 5). A control experiment was performed in the absence of immobilized
MacB inwhich20MacAwas passed through aNi2-agarose column and the
flow-through (lane 7), the first and second washes with 100 mM imidazole
(lanes 8 and 9, respectively), and the 500mM imidazole elution (lane 10) were
tested for the presence of MacA, which was only found in the flow-through
and first wash (lane 7 and 8, respectively), establishing that S-tagged MacA
does not bind to the column. These results indicate that MacA does not
require the N-terminal -helix, which anchors it to the inner membrane, to
interact with MacB. A proteinMr marker was run in lane 6.
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RESULTS
MacA Interacts with BothMacB and TolC via Its Periplasmic
Domain—Interactions between E. coliMacA, MacB, and TolC
were tested using detergent-solubilized proteins for pulldown
assays (Fig. 1). MacA interacted with MacB (Fig. 1B), which we
confirmed by cross-linking the proteins (supplemental Fig. 2A),
and TolC (Fig. 1C). Althoughwe detected an interaction between
TolC and MacB (Fig. 1D), the intensity of the band suggested a
weak interaction.N-terminal truncatedMacA (20-MacA) inter-
acted with MacB (Fig. 1E), indicating that it is the periplasmic
domains of these proteins that interact. The fact that in each case
the cognate pump protein could be pulled out of a complex mix-
ture of detergent-solubilized proteins from membranes or cells
indicated that the interactions are specific.
E. coli MacA and MacB Form a Functional Complex with
TolC—The simultaneous expression of macA, macB, and tolC
in the E. coli acrAB strain KAM3 (26) conferred resistance to
erythromycin, indicative of the formation of a functional com-
plex (Fig. 2A). Cells expressingmacBwith tolC conferred mod-
est resistance to erythromycin in comparison with cells
expressing macB, tolC, and macA, indicating that MacA is
required to couple MacB to TolC (Fig. 2A). We sought to test
whether the N terminus ofMacA, which incorporates an -he-
lix that could interact withMacB, is required for the functional
assembly of the complex. A construct in which the gIII-signal
sequence was fused to truncated MacA, targeting it to the
periplasm, was capable of conferring resistance to erythromy-
cin (Fig. 2A), indicating that the N-terminal domain is not
essential for the assembly of the functional complex. This is
consistent with a report that a truncated lipid-deficient AcrA
derivative was functional as judged by resistance of the cells to
erythromycin (27).MacB alone conferred elevated resistance to
erythromycin, probably because of its ability to pump the anti-
biotic into the periplasm, but we consistently found that
expressing macB with either tolC or macA conferred greater
resistance. Consequently, we sought to test if MacA could
enhance this ability. To overcome the difficulty in comparing
the growth of cells overexpressing multiple proteins that tend
to grow at different rates, we monitored the growth of cells in
the presence and absence of erythromycin and determined the
growth loss (for cells growing in the presence of erythromycin
in comparison with cells growing in the absence of erythromy-
cin) (Fig. 2B). This revealed a significant loss in growth of the
cells expressingMacB comparedwith those expressingMacAB,
indicating that the simultaneous expression ofMacA andMacB
increases the resistance of the cells to erythromycin (Fig. 2B),
suggesting that MacA enhances the ability of MacB to confer
antibiotic resistance. Similarly, a previous study reported that
MacAB, but not MacB alone, conferred resistance to macroli-
des (3).
MacB Forms Dimers—MacB has an atypical structure for an
ABC transporter as it is predicted to have an N-terminal cyto-
plasmic NBD, which is connected to a four-helix transmem-
brane domain, with a large periplasmic domain formed by the
loops connecting helices 1 and 2 (3, 23). If MacB resembles
other ABC transporters that use a pair of NBDs to bind ATP,
then it should function as a dimer. However, many transport-
ers, including ABC transporters, have 12 membrane-spanning
helices; MacB could adopt a similar topology by forming trim-
ers. Furthermore, AcrB (4, 5) andTolC (9), which assemble into
a tripartite complex with AcrA, clearly form trimers. If the tri-
meric arrangement of the periplasmic domains in AcrB forms a
necessary scaffold for binding of AcrA, so that it can effectively
interact with TolC, then by analogy the periplasmic domain of
MacBmight also be forced into forming trimers when interact-
ing with MacA and TolC.
Therefore, we sought to determine the oligomeric state of
MacB. Size-exclusion chromatography indicated that it forms
higher order oligomers consistent with a dimer (data not
shown), but such measurements are not only dependent upon
themolecular weight but also the shape of the protein. Further-
more, there is a need to determine the number of detergent
molecules complexed by the protein. Consequently, to deter-
mine whether the detergent-solubilized MacB was dimeric, we
added a cross-linker to trap the oligomers; when we ran the
cross-linked protein on an SDS-polyacrylamide gel, the most
predominant band ran between the 120- and 160-kDamarkers,
FIGURE 2.MacAB-TolC form a tripartite complex that confers resistance
to erythromycin. A, growth curves for E. coli cells, of strain KAM3 (DE3), har-
boring the plasmids pETDuet (F), pETDuet-MacB (E), pETDuet-MacB/MacA
(), pETDuet-MacB/TolC (‚), pETDuet-MacB/MacA/TolC (f) and pETDuet-
MacB/gIII-SS-20MacA/TolC () grown in the presence of 100 g/ml eryth-
romycin. B, bar chart showing the extent of inhibition of the growth of E. coli
cells in response to 50 g/ml erythromycin, of strain KAM3(DE3), harboring
the plasmids pETDuet (blank), pETDuet-MacB (MacB), pETDuet-MacB/MacA
(MacAB) or no plasmid (Wild). For each strain the A600 was determined after
growth for 3 h in the absence and presence of erythromycin, and the growth
inhibitionwas determined as the ratio of thesemeasurements. Cells express-
ing both MacA and MacB suffered less from erythromycin growth inhibition
than those expressing only MacB, suggesting that MacA confers elevated
resistance to erythromycin on the MacB strain.
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indicative of a dimer, which has a calculated molecular mass of
145.8 kDa (supplemental Fig. 2B).
To further confirm the basic oligomeric unit as a dimer, we
used two other techniques, analytical ultracentrifugation
(AUC) and electrospray mass spectrometry (ES-MS). For the
AUC experiments, we reduced the DDM concentration to
just below the criticalmicelle concentration to avoid the forma-
tion ofmicelles. To determine the detergent contribution in the
buoyant mass of the protein-detergent complex, we used a
series of different density buffers prepared using a range of D2O
concentrations. The apparent molecular mass for MacB was
determined from sedimentation equilibrium measurements to
be 162.6 kDa (Fig. 3A) and from sedimentation velocity meas-
urements to have a sedimentation coefficient of 6.8 S, corre-
sponding to a molecular mass of 160.0 kDa (Fig. 3B). This
molecular mass is greater than expected for monomeric and
less than expected for trimeric MacB, complexed with bound
detergent, but it is highly consistent with a MacB dimer to
which about 16 DDM molecules are bound. Although the
amount of detergent bound to the MacB dimer appears to be
lower than reported for RND (28) and MF (29) transporters,
this reflects the fact that in our experimental set-up the deter-
gent contribution was actively suppressed using a solvent den-
sity matching technique (25). Our independent measurement
of bound detergent using a calorimetric assay (30) indicated
that, when the detergent concentration was close to the critical
micelle concentration, the amount of bounddetergentwas sim-
ilar to that of othermembrane proteins (e.g.MacB solubilized in
0.05% w/v DDM bound 1.2 g of DDM/g of MacB, which is
equivalent to a DDM:MacB molar ratio of 164:1). Electros-
pray-mass spectrometry (ES-MS) was used in nontandem con-
figuration to determine accurately the molecular mass of the
protein, under conditions that would dissociate the DDM,
revealing a peak with a molecular mass of 145,961.25  20.57
Da that is consistent with a MacB dimer (Fig. 3C).
We also sought to visualize single particles of MacB by AFM
(Fig. 4, A and D). Two populations were revealed with average
molecular volumes of 118 and 238 nm3 (Fig. 4B). These would
accommodate proteins of about 60–70 and 130–140 kDa,
respectively. Furthermore, the larger particles could clearly be
seen at higher resolution to consist of two protein domains that
are highly suggestive of a dimer. We found that in the presence
of AMP-PNP, a nonhydrolysable analogue of ATP, the ratio of
dimers to monomers on the AFM grids increased (Fig. 4C),
which would be consistent with the nucleotide stabilizing the
interaction betweenmonomers.Our findings are novel because
detergentmolecules tend to impair the resolution ofAFMstud-
ies of detergent-solubilized membrane proteins; this implies
that for MacB, we may be able to get information on the topol-
ogy and stoichiometry of its assemblies with MacA and TolC.
Indeed, under coincubation of MacA and MacB, we could
clearly distinguish a significant distribution of particles with
molecular volumes larger than those corresponding to MacB
dimers, which is consistent with multiprotein complexes
formed between both proteins (data not shown). Such promis-
ing data paves theway toward further characterization ofmem-
brane multiprotein complexes and could prove a powerful
instrument for determining the stoichiometry of the tripartite
assembly.
MacA Regulates the ATPase Activity of MacB—MacB
retained ATPase activity when detergent-solubilized, but this
was detergent-dependent, being active in Triton X-100 but not
in DDM (data not shown). The time course for hydrolysis of
MgATP by MacB was determined in a stopped-flow spectro-
photometer, using the dye 2-amino-6-mercapto-7-methylpu-
rine riboside tomonitor the production of inorganic phosphate
(Pi). The time course was characterized by a burst in Pi produc-
tion, during the first 20 s, followed by a slower steady-state rate
(Fig. 5A). This kinetic behavior is consistentwith theATPbeing
rapidly hydrolyzed, to produce Pi and ADP, but further turn-
overs are rate-limited either by a subsequent conformational
change or the slow release of products. Because previous stud-
ies have established that the ATPase activity of MacB is inhib-
ited by vanadate (24), which stabilizes bound ADP, this indi-
cates that Pi is released before ADP, suggesting that ADP
release is rate-limiting. The rate constant for the hydrolysis step
was determined by fitting the burst phase to an exponential
function, yielding a kcat value of 0.24 s1, whereas the amplitude
of the burst phasewas 2.2M for 1mMATP (Fig. 5A).When the
MacA and MacB concentrations were increased to 3.5 M, the
amplitude of the burst phase increased to 3.3 M (data not
shown), indicating that the burst is approximately equivalent to
the MacB concentration and that both NBDs within the MacB
FIGURE 3. Biophysical evidence for MacB dimer formation. A, AUC sedi-
mentation equilibrium profiles of MacB. A representative sedimentation
equilibrium profile from one of the runs (two different velocities of the same
sample) is shown. Experimental data (dots) and fitted model for a 162.6-kDa
particle (solid line) is shown for each. The bottom panel represents the residu-
als after fitting. B, AUC sedimentation velocity profiles of MacB are consistent
with the formation of a stable dimer. The upper panel shows sedimentation
profile curves at different time points, and the lower panel presents a c(s) size
distribution analysiswith solutionsof the Lammequation. The sedimentation
coefficient is 6.8 S corresponding to an apparent molecular mass of 160 kDa,
consistent with a dimer with about 16 detergent molecules bound. C, mass
spectrum of MacB. The charge states corresponding to the peaks are
graphed. The mass spectrum indicated a molecular mass for MacB of 145.96
kDa, which is consistent with a dimer.
MacBDimer Is Regulated byMacA
JANUARY 9, 2009•VOLUME 284•NUMBER 2 JOURNAL OF BIOLOGICAL CHEMISTRY 1149
dimer are functional. We did not notice any deviation from a
single exponential that would indicate that these NBDs turn
over ATP differentially. The steady-state phase was character-
ized by a rate of Pi production that increased in a hyperbolic
manner with the ATP concentration (Fig. 5B); fitting the
steady-state rate data to a hyperbolic function yielded a maxi-
mal specific activity of 8.9 nmol of ATP/min/mg MacB and a
Km of 374 M. A progressive reduction in the amplitude of the
burst phase for ATP concentrations below the steady-state Km
value hindered analyses because the pre-steady-state phase
tended to merge with the steady-state phase; consequently, we
only used the steady-state rates determined at ATP concentra-
tions of 0.1 mM and above. For comparison, the lipid A trans-
porter MsbA, an half-ABC transporter, was characterized by a
Vmax of 37 nmol of ATP/min/mg and a Km of 878 M (31).
WhenMacA was added toMacB,
at an equivalent or higher concen-
tration, with both proteins in deter-
gent, no phosphate burst was
observed (Fig. 5A). Considering that
the detergent was present for both
the ATPase assays with MacB and
MacAB suggests that the burst
phase is mechanistically important
and cannot be attributed to the
detergent modifying the behavior of
MacB. Interestingly, although there
was no Pi burst byMacB in the pres-
ence of MacA, there was a lag in Pi
production; this could signify that a
conformational change that pre-
cedes the hydrolysis step becomes
rate-limiting for the first turnover.
The steady-state rate of ATP hy-
drolysis byMacB, in the presence of
MacA, was enhanced (Fig. 5B). At
first glance, this behavior might
appear consistent with MacA in-
creasing the rate of ADP dissocia-
tion from MacB, so that this step
was no longer rate-limiting. How-
ever, although MacA increased the
specific activity of MacB from 8.9 to
12.3 nmol of ATP/mg MacB/min,
which would correspond to an in-
crease in kcat from 0.011 to 0.015
s1, the steady-state rate did not
exceed the rate for hydrolysis in the
absence of MacA (e.g. 0.24 s1) (Fig.
5B). Accordingly, the increase in the
steady-state rate, whichwe attribute
to product release, or a conforma-
tional change preceding this, would
not be rapid enough to prevent the
phosphate burst. It seems more
likely that MacA also retards the
rate of ATP hydrolysis, so that this
process becomes slower than the
rate of product release. Indeed, we found that the affinity of
MacB for ATP was increased by more than 5-fold, from 374 to
72 M, in the presence of MacA (Fig. 5B). If the effect of MacA
was simply to enhance product release to a rate faster than that
for nucleotide hydrolysis, then we would have expected a
decrease in affinity for ATP. On the other hand, ifMacA simply
retarded nucleotide hydrolysis to a rate slower than product
release, then the maximal steady-state rate would have
decreased. Our data are consistent with MacA increasing the
rate of product release, while decreasing the rate of hydrolysis
to a similar rate to product release.
In contrast to a previous study, which indicated that the
ATPase activity of reconstituted MacB was not activated by
N-terminal truncated MacA (24), we found that when MacB
was mixed with 20-MacA no Pi burst was apparent (data not
FIGURE4.AFManalyses,AFM imagingofMacB.A, three-dimensional pictureof a lowmagnification imageof
MacBacquired in air in TappingModewith adiamond-like extra tipof resonant frequency	300kHzand spring
constant of 40 newtons/m.m and d show particles that belong to the first and second peak in B, respectively.
B, frequency distribution of molecular volumes of MacB. The curve indicates a fitted Gaussian function. Them
and d peaks correspond to volumes of 118 1 nm3 (n
 1642) and 238 5 nm3 (n
 665), consistent with the
monomer and dimer, respectively. C, frequency distribution of molecular volumes of MacB that had been
incubated with the nonhydrolysable ATP analogue AMP-PNP. The peaks correspond to volumes of 112  3
nm3 (n
 94) and 218 14 nm3 (n
 116). These data indicate an increase in the dimer:monomer ratio in the
presenceofAMP-PNP.D,high resolution imagesof structureswhere two small particles (mm) are attached to
one another, clearly indicative of dimer formation.
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shown). In the same study, and consistent with our findings,
N-terminal truncatedMacA was shown to interact withMacB;
however, in contrast to our findings, whenMacBwas expressed
with N-terminal truncated MacA in erythromycin-susceptible
cells, therewas no increase in erythromycin resistance (24). The
reason for the difference with our own findings is unclear; how-
ever, in the previous study the signal sequence of OmpA was
used to target MacA, truncated at position 32, to the periplasm
(24), raising the possibility that the shorter MacA sequence
and/or the OmpA signal sequence interfered with the ability of
MacA to affect the ATPase activity of MacB.
In accord with previous studies (24), we could not detect an
effect of erythromycin on the kinetics ofMacBATPase either in
the absence or presence of MacA (data not shown). Recent
studies have established that the ATPase activity of Pdr5 is
uncoupled from substrate binding; this basal ATPase activity
might be required to constantly cycle the transporter between
conformations, so as to maintain the accessibility of the cyto-
solic substrate-binding site (32). In the case ofMacB, itsATPase
activity might instead be stimulated by TolC, to reset its con-
formation following drug transfer to TolC.
MacA Increases the Capacity of MacB to Bind Erythromycin—
Althoughwe could not detect any effect of erythromycin on the
ATPase activity of MacB, we could detect the binding of
[14C]erythromycin to detergent-solubilized MacB (Fig. 6).
Importantly, we found that the MacAB complex bound more
erythromycin than MacB alone (which binds considerably
more than MacA alone) and that the amount bound increased
in a concentration-dependent manner, as would be expected if
MacA increased the affinity of MacB for erythromycin. How-
ever, because of the insolubility of the antibiotic in aqueous
solutions, it was not possible to test a full range of erythromycin
concentrations that might saturate MacAB. Consequently, we
cannot exclude the possibility of the formation of additional
sites within theMacAB complex that are not apparent in either
MacB or MacA alone. Our data indicate that MacA not only
modulates the ATPase activity of MacB but also enhances its
capacity to bind erythromycin (be this due to an increase in
affinity of MacB for drugs or the formation of additional drug-
binding sites within the MacAB complex).
DISCUSSION
Gram-negative bacteria possess tripartite pumps that facili-
tate the extrusion of protein toxins and cytotoxic compounds,
such as antibiotics, from the cell. In these tripartite assemblies
the IMP is coupled to anOMP by a periplasmicMFP, forming a
pump that can translocate molecules across both the inner and
outer membranes. Intriguingly, Gram-positive bacteria that
lack an outer membrane also possess MFPs, suggesting that
they play a role in addition to stabilizing the interaction of the
IMP with the OMP. Indeed, we have noted in some of these
MFPs a large deletion corresponding to the coiled-coil hairpin
that would interact with the OMP (supplemental Fig. 1). To
FIGURE 5.MacA regulates the ATPase activity of MacB. A, time course for
the change in Pi concentration, corresponding to the absorbance change of
the 2-amino-6-mercapto-7-methylpurine riboside in A, where 2.3 M MacB
was mixed with 1 mM ATP in the absence (upper trace) and presence (lower
trace) of an equivalent concentration of MacA. In the absence of MacA, MacB
produced a phosphate (Pi) burst, with a rate and amplitude of 0.235 (0.001)
s1 and 2.20 (0.01) M, respectively. MacB did not produce a Pi burst in the
presence of MacA. B, steady-state rate of Pi production byMacB as a function
of the ATP concentration in the absence (lower curve) and presence (upper
curve) of an equivalent concentration of MacA. The data are characterized by
Vmax and Km values of 8.9 (0.7) nmol of ATP/mg MacB/min and 374 (126)
M, respectively, for MacB alone; and of 12.3 (0.5) nmol of ATP/mg MacB/
min and 72 (22)M, respectively, for MacB in the presence of an equivalent
concentration of MacA.
FIGURE 6. MacA increases the capacity of MacB to bind erythromycin.
Purified proteins (50 g of MacA or MacB, or 25 g of MacA plus 25 g of
MacB) were incubated in the presence of [N-methyl-14C]erythromycin at con-
centrations as indicated (1, 5, or 10 M), after which drug binding was meas-
ured by rapid filtration. The bars represent the erythromycin bound byMacA
(left, black), MacB (middle, light gray), and MacAB (right, dark gray). The data
indicate that MacA enhances the binding of erythromycin to MacB.
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investigate this possibility, we sought to determine the role of
MacA, the MFP that couples the IMP MacB, an ATP-driven
transporter, with the OMPTolC in E. coli to extrudemacrolide
antibiotics (3). We established that MacA interacts with both
MacB and TolC (Fig. 1) to form a functional tripartite complex
(Fig. 2).However, we also found thatMacAenhanced the resist-
ance to erythromycin conferred by MacB alone (Fig. 2B), sug-
gesting that it modulated the transport activity of MacB, which
is consistent with our data demonstrating that MacA regulates
the drug binding and ATPase activity of MacB (Figs. 5 and 6).
The role of theMFPBesA in the activity of the BesABCpump in
Borrelia burgdorferi, the causative agent of Lyme disease, has
recently been highlighted (33). It is quite remarkable that in this
system BesA also lacks the -helical hairpin. As such this
periplasmic protein is unable to unlock the periplasmic entry
site of theOMP, a function that is attributed to the hairpin (11).
To compensate, theOMPhas evolved to be constitutively leaky.
The reason for the retention of BesA in the Borrelia system is
most likely associated with its function in the activation of the
inner membrane component, in that case an RND transporter.
It is conceivable then, that a similar role is also present in the
ABC transporters and their associated MFPs, and it could
explain the preservation of the hairpin-lacking MFPs in Gram-
positive bacteria, such as S. aureus (supplemental Fig. 1).
Although E. coli MacB has an NBD, which incorporates
Walker A and Bmotifs and an ABC signature sequence that are
characteristic features of members of the ABC superfamily, it is
not a classicABC transporter. It has a large periplasmic domain,
reminiscent of that found in RND transporters, which form
trimers in which these domains form substantive sites of con-
tact between the protomers. Consequently, we sought to deter-
mine the oligomeric state of MacB and in doing so have devel-
oped a novel ES-MS approach to unambiguously establish that
MacB forms dimers (Fig. 3C). ES-MS is now widely accepted as
a powerful method to determine accurately the stoichiometry
of intact protein complexes (34). However membrane proteins,
solubilized by detergent or adsorbed inmicelles, have remained
difficult to analyze under similar MS conditions. The develop-
ment of strategies to tackle this field is challenging, primarily
because the large quantities of detergent suppress the protein
signal, whereas the poor solubility of membrane proteins in
aqueous buffers often causes the electrospray needle to block.
To date only a fewMS studies have reported the observation of
membrane proteins or their complexes byMS (35–39).Herewe
report on the use of a miniaturized form of ES with reduced
flow rates (nano-ES), and a high collision energy that facilitates
the desolvation process and induces dissociation of detergent-
proteins clusters, to determine the oligomeric state of an inte-
gral homomeric membrane protein. In our protocol we used
lower quantities ofDDM, than have been reported previously,
without apparent detrimental effects on the stability of the pro-
tein. Under our experimental conditions, we have successfully
maintained the noncovalent subunit interactions, such that the
oligomeric state of the protein complex could be determined
without ambiguity. As would be expected for an ABC trans-
porter in which the NBDs interact, our biophysical studies of
MacB indicate that it forms dimers (Figs. 3 and 4 and supple-
mental Fig. 3). This is an interesting observation because it
raises the following question. How does dimeric MacB interact
with trimeric TolC and the number ofMacAmolecules needed
to stabilize the tripartite complex? Extension of our AFM stud-
ies will be vital for determining the stoichiometry of the inter-
actions to provide an understanding of the assembly of the tri-
partite complex, which may be difficult to address by other
methods, such as crystallization of the complex.
Our findings and previous studies, which have shown that
disruption of the Walker A and B motifs not only inhibits the
ATPase activity but also blocks the capacity of MacB to confer
macrolide resistance (24), suggest thatMacB operates by a sim-
ilar mechanism to typical ABC transporters. Our understand-
ing of how ABC transporters couple ATP hydrolysis to trans-
port is still rudimentary, but the determination of the crystal
structures of several ATPase subunits and completeABC trans-
porters has suggested conservation of key steps in the molecu-
lar mechanism. The binding of ATP to both soluble ATPase
subunits (40), solubilized NBDs from ABC transporters (41,
42), and to the NBDs within a complete ABC transporter (43,
44) has been shown to promote dimerization as the ATP is
bound at the interface of these nucleotide-binding sites, sand-
wiched between the Walker A motif of one NBD and the ABC
signature motif of the other NBD. Our AFM studies indicated
that there is a higher proportion of MacB dimers in the pres-
ence of the nonhydrolysable nucleotide AMP-PNP (Fig. 4). In
complete ABC transporters, the binding of ATP causes the
transporter to adopt a conformation in which the substrate-
binding site is outward-facing, because ATP bridges the two
NBDs, closing off the inward-facing substrate-binding site (45).
Conversely, the release of the hydrolysis products ADP and
phosphate is thought to promote an inward-facing conforma-
tion, as the structural constraint imposed by binding of the
nucleotide is released. Consistent with this proposal, several
studies indicate that NBD dimerization cannot be induced by
ADP (46), because interactions between the -phosphate of
ATP and the signature sequence catalyze these events (47). We
found that MacA modulates these processes in MacB (Fig. 5),
and so our kinetic data have clear implications in terms of such
a mechanism. Most significantly, MacA increases the apparent
affinity of MacB for ATP, while decreasing the rate of ATP
hydrolysis, so as to promote and stabilize the ATP binding con-
formation, which we presume to be the conformation in which
the antibiotic-binding site is outward-facing. In this manner,
MacA would play a direct role in driving antibiotic transloca-
tion between MacB and TolC.
During the course of our studies another investigation
reported on the effect of MacA on the steady-state ATPase
activity of MacB (24). In this study, MacB, solubilized in Triton
X-100, appeared to have a specific activity that was an order of
magnitude higher thanwehad found; however, a discontinuous
assay was used to determine the ATPase activity, and this could
well have been influenced by pooling the time points from both
the burst and steady-state phases. Indeed, kcat was marginally
slower than the hydrolysis rate determined from the Pi burst
phase in our experiments (e.g. 0.17 versus 0.24 s1). Possibly for
similar reasons, this assay did not detect the effect of MacA on
MacB solubilized in Triton X-100. However, they did find that
MacB reconstituted into liposomes was characterized by a
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reduced kcat (e.g. kcat
 0.10 s1) and decreased affinity ofMacB
for ATP (e.g. Km 
 2.30 mM). Co-reconstitution of MacB with
MacA had the effect of increasing both kcat (e.g. kcat
 0.78 s1)
and the affinity of MacB for ATP (e.g. Km 
 0.38 mM). This
behavior is similar to the effect of MacA on the steady-state
kinetics of theATPase activity of solubilizedMacB in our study.
To know if the reconstituted protein behaves in an identical
manner to the solubilized protein would require the reconsti-
tution of sufficient amounts of MacB to define any Pi burst,
which is technically demanding. Consequently, although these
earlier studies support our conclusion that MacA affects the
ATPase activity of MacB, they do not give the detailed insight
into the ATPase mechanism provided by our pre-steady-state
analyses.
Our studies established that conformational changes can be
propagated from the periplasmic domain of MacA to the cyto-
plasmic NBD of MacB (Figs. 1 and 2), and consequently, it is
plausible that TolC, by interacting with MacA, can detect the
nucleotide state of MacB. The binding of ATP to MacB would
stimulate MacA to interact with TolC, inducing the latter to
adopt the open state. Because ATP and MacA stabilize in the
outward-facing conformation of MacB, drug transfer from
MacB to TolC would be facilitated. TolC would then commu-
nicate with the NBD of MacB (again, such communication is
probably conveyed via MacA) to stimulate ATP hydrolysis,
which would be required to reset MacB in the inward-facing
conformation. If ATP hydrolysis is controlled by TolC, so that
the MacB conformation is only reset after the interaction with
TolC and productive transfer of drugs, this would provide an
explanation of the apparent insensitivity of the ATPase activity
of MacB to drugs. Indeed, without such a feedback control
mechanism of drug export, it would appear that drug stimula-
tion of the ATPase activity of MacB would be counter-produc-
tive because theMacB conformation could be reset before drug
transfer to TolC. There is an analogy in themechanism of oper-
ation of ABC transporters that work in conjunction with a
periplasmic binding protein (47). In the E. coli maltose trans-
porter, the binding ofATP to theATPase subunitMalK induces
conformational changes, detected by tryptic digestion, in the
periplasmic loops of the membrane subunits MalF and MalG
(48), whilst EPR studies revealed that ATP binding, but not
ADP binding, caused an increase in affinity between the trans-
porter and the maltose-binding protein (MBP), and “forcing
open” the bound MBP to release its substrate (49). The trans-
porter is reset in its original inward-facing conformation by
ATP hydrolysis, which is stimulated by the MBP (50). In our
model TolC replaces the MBP and, because the open state
requires disruption of the second selectivity filter and subse-
quent twisting of the helices of the TolC channel to keep it fully
open, there is a need for the MacA hairpins to stabilize this
conformation, which could not be achieved by interaction with
MacB alone. Although we have interpreted our findings in
terms of an alternating conformationmodel forMacB, inwhich
the drug-binding sites are inwardly and outwardly exposed,
such amodel could easily be refined to account for drug binding
to a fixed periplasmic site, in analogy toAcrB,withATPbinding
and hydrolysis coupled to conformational changes that induce
TolC association and dissociation. Clearly the work presented
here provides an important framework for further studies that
will enable the elucidation of the mechanism underlying the
dynamics of assembly of theMacABTolC tripartite pump in the
future.
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